You are here

Topical Erectile Dysfunction Drug, Topiglan, Enters Phase II Trial

LEXINGTON, Mass., Aug. 26 /PRNewswire-FirstCall/ -- MacroChem Corporation (Nasdaq: MCHM) announced today that it is expanding a double-blind Phase 2 clinical trial of Topiglan(R), its easy-to-apply topical cream for erectile dysfunction (ED), into the United States. Trial sites in the U.S. will follow the same protocol as that of an ongoing trial in the United Kingdom, where this innovative treatment is being tested in men with mild-to-moderate ED. Topiglan combines alprostadil, a well-proven vasodilator, with SEPA(R), MacroChem's patented drug-absorption enhancer. (Note to editors: Photo of Topiglan prototype package available upon email request to

"Recent news of the imminent availability of Levitra(R) in the U.S. will heighten awareness of available therapies as well as their limitations," explained Robert J. DeLuccia, president and chief executive officer of MacroChem. "Many patients and their physicians are concerned about the risks of drug-drug interactions and systemic side effects of the oral ED medications. We believe both doctors and patients will be attracted to a truly topical, easy-to-apply, locally acting alternative like Topiglan."

"The alprostadil in Topiglan is different from the active ingredients in the oral 'PDE-5 inhibitor' ED drugs," Mr. DeLuccia said. "Alprostadil alone isn't adequately absorbed when applied locally, and must be either injected or inserted into the urethra as a suppository. SEPA in Topiglan facilitates penetration of alprostadil through skin and into erectile tissues."

MacroChem believes that a truly topical alprostadil formulation could theoretically offer significant advantages over oral ED medications. Those advantages include no significant systemic side effects; rapid onset of action; and low risk of systemic interaction with any known cardiovascular drug.

"We are advancing the clinical development of Topiglan consistent with our global plan by expanding this trial into the U.S., the world's largest ED market," Mr. DeLuccia said. "Expanding the scope of this trial enables U.S. investigators who had successful experience with our first-generation gel to evaluate our new cream formulation."

This Phase 2 study builds on the successful Phase 1 data with the new cream formulation, which appeared to be better tolerated than the first generation gel. It also builds on the previously completed home trial of the gel, in which a 435-patient protocol-conforming subset of 550 men with moderate-to-severe ED achieved statistically significant improvement in both primary end points: Improvement in IIEF erectile function score and improvement in intercourse completion.

As in the current U.K. trial, the new U.S. sites will utilize the same RigiScan(R) monitoring technique to compare the response of men with erectile dysfunction to Topiglan or a placebo cream. This RigiScan technology has been used by developers of oral ED drugs to predict the likely efficacy of their products.

About MacroChem:
MacroChem innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. In addition to Topiglan, MacroChem is developing two other products containing its patented drug-absorption enhancer, SEPA(R): Opterone(TM), a SEPA-enhanced testosterone for men with hypogonadism; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis.

More information is available at the web site:

Source: MacroChem

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs